Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110426 | 0.85 | HTR2C (0.52) | HTR2CHTR2AP2RX7PRMT5HTR6 | |
| SCHEMBL24110621 | 0.82 | KRAS (0.32) | HTR2CHTR2AHTR6 | |
| SCHEMBL24110433 | 0.81 | HTR2C (0.53) | HTR2CHTR2APRMT5HTR6FABP4 | |
| SCHEMBL24110205 | 0.79 | HTR2A (0.32) | HTR2CHTR2A | |
| SCHEMBL24110421 | 0.77 | — | — | |
| SCHEMBL24110194 | 0.77 | HTR2A (0.36) | HTR2CHTR2A | |
| SCHEMBL24110430 | 0.76 | HTR2A (0.54) | HTR2CHTR2AHTR6KMT2A | |
| SCHEMBL24110201 | 0.76 | ADRA2A (0.48) | HTR2CHTR2AP2RX7THRB | |
| SCHEMBL24110193 | 0.75 | HTR2C (0.37) | HTR2CHTR2A | |
| SCHEMBL24110503 | 0.74 | HTR2A (0.38) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2C 35/4885HTR2A 10/4885P2RX7 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.